Plain-English translation of NCT02784171 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Mesothelioma research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial tested a medication called combined with standard chemotherapy drugs ( and ) in patients with advanced malignant pleural mesothelioma — a serious cancer of the lung lining. Researchers compared how well this new treatment combination worked against the standard chemotherapy alone, and also examined how the treatment affected side effects and quality of life.
Standard chemotherapy has only limited success in treating advanced mesothelioma, and doctors were investigating whether adding an immunotherapy medication could help patients live longer and respond better to treatment.
Participants were randomly assigned to receive one of three treatment options: standard chemotherapy alone, standard chemotherapy combined with the immunotherapy medication, or the immunotherapy medication alone (in the earlier phase of the trial). Those receiving the combination or immunotherapy alone received infusions of the medication every 3 weeks for up to 2 years, while chemotherapy was given for 6 cycles (about 18 weeks). Participants had regular visits for blood tests, imaging scans, and check-ups to monitor how well the treatment was working and to track any side effects.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
Canada